ENDRA Life Sciences (NDRA) Accounts Payables (2016 - 2026)

ENDRA Life Sciences (NDRA) has 11 years of Accounts Payables data on file, last reported at $701487.0 in Q1 2026.

• Accounts Payables for Q1 2026 came in at $701487.0, up 59.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $701487.0 (up 59.54% YoY), and the FY2025 annual result was $621578.0, up 22.29% from the prior year.
• Accounts Payables grew to $701487.0 in Q1 2026 per NDRA's latest filing, from $621578.0 in the prior quarter.
• Over five years, Accounts Payables peaked at $2.0 million in Q3 2023 and troughed at $439688.0 in Q1 2025.
• A 5-year average of $1.1 million and a median of $1.0 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2026: Accounts Payables tumbled 68.23% in 2024, then jumped 59.54% in 2026.
• A 5-year view of Accounts Payables shows it stood at $1.5 million in 2022, then plunged by 53.99% to $700754.0 in 2023, then declined by 27.46% to $508293.0 in 2024, then increased by 22.29% to $621578.0 in 2025, then advanced by 12.86% to $701487.0 in 2026.
• Business Quant data shows NDRA's Accounts Payables at $701487.0 in Q1 2026, $621578.0 in Q4 2025, and $671516.0 in Q3 2025.